Cargando…

Outcome and Safety after 103 Radioembolizations with Yttrium-90 Resin Microspheres in 73 Patients with Unresectable Intrahepatic Cholangiocarcinoma—An Evaluation of Predictors

SIMPLE SUMMARY: TARE with yttrium-90 (90Y) resin microspheres is emerging in many countries as a treatment option for ICC. Identification of patients that will benefit from TARE is a clinically relevant problem with individual but also economical relevance. The aim of this study was to detect outcom...

Descripción completa

Detalles Bibliográficos
Autores principales: Paprottka, Karolin J., Galiè, Franziska, Ingrisch, Michael, Geith, Tobias, Ilhan, Harun, Todica, Andrei, Michl, Marlies, Nadjiri, Jonathan, Paprottka, Philipp M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582544/
https://www.ncbi.nlm.nih.gov/pubmed/34771563
http://dx.doi.org/10.3390/cancers13215399
_version_ 1784597011489619968
author Paprottka, Karolin J.
Galiè, Franziska
Ingrisch, Michael
Geith, Tobias
Ilhan, Harun
Todica, Andrei
Michl, Marlies
Nadjiri, Jonathan
Paprottka, Philipp M.
author_facet Paprottka, Karolin J.
Galiè, Franziska
Ingrisch, Michael
Geith, Tobias
Ilhan, Harun
Todica, Andrei
Michl, Marlies
Nadjiri, Jonathan
Paprottka, Philipp M.
author_sort Paprottka, Karolin J.
collection PubMed
description SIMPLE SUMMARY: TARE with yttrium-90 (90Y) resin microspheres is emerging in many countries as a treatment option for ICC. Identification of patients that will benefit from TARE is a clinically relevant problem with individual but also economical relevance. The aim of this study was to detect outcome predictors for patients with ICC after TARE with 90Y resin microspheres. We found TARE with 90Y resin microspheres to be a safe treatment option for unresectable ICC. Predictive factors for TARE in ICC are CA-19-9 response, tumor burden, and cholinesterase. Multiple TARE sessions might further improve overall survival. ABSTRACT: Trans-arterial radioembolization (TARE) is increasingly evaluated for unresectable intrahepatic cholangiocarcinoma (ICC). Not all ICC patients benefit equally well from TARE. Therefore, we sought to evaluate variables predicting progression-free survival (PFS) and overall survival (OS). Patients with non-resectable ICC underwent TARE and were treated with 90Y resin microspheres. Baseline characteristics, biochemical/clinical toxicities, and response were examined for impact on PFS and OS. A total of 103 treatments were administered to 73 patients without major complications or toxicity. Mean OS was 18.9 months (95% confidence intervals (CI); 13.9–23.9 months). Mean and median PFS were 10.1 months (95% CI; 7.9–12.2) and 6.4 months (95% CI; 5.20–7.61), respectively. Median OS and PFS were significantly prolonged in patients with baseline cholinesterase (CHE) ≥ 4.62 kU/L (OS: 14.0 vs. 5.5 months; PFS: 6.9 vs. 3.2 months; p < 0.001). Patients with a tumor burden ≤ 25% had a significantly longer OS (15.2 vs. 6.6 months; p = 0.036). Median PFS was significantly longer for patients with multiple TARE cycles (24.4 vs. 5.8 months; p = 0.04). TARE is a considerable and safe option for unresectable ICC. CA-19-9, CHE, and tumor burden have predictive value for survival in patients treated with TARE. Multiple TARE treatments might further improve survival; this has to be confirmed by further studies.
format Online
Article
Text
id pubmed-8582544
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85825442021-11-12 Outcome and Safety after 103 Radioembolizations with Yttrium-90 Resin Microspheres in 73 Patients with Unresectable Intrahepatic Cholangiocarcinoma—An Evaluation of Predictors Paprottka, Karolin J. Galiè, Franziska Ingrisch, Michael Geith, Tobias Ilhan, Harun Todica, Andrei Michl, Marlies Nadjiri, Jonathan Paprottka, Philipp M. Cancers (Basel) Article SIMPLE SUMMARY: TARE with yttrium-90 (90Y) resin microspheres is emerging in many countries as a treatment option for ICC. Identification of patients that will benefit from TARE is a clinically relevant problem with individual but also economical relevance. The aim of this study was to detect outcome predictors for patients with ICC after TARE with 90Y resin microspheres. We found TARE with 90Y resin microspheres to be a safe treatment option for unresectable ICC. Predictive factors for TARE in ICC are CA-19-9 response, tumor burden, and cholinesterase. Multiple TARE sessions might further improve overall survival. ABSTRACT: Trans-arterial radioembolization (TARE) is increasingly evaluated for unresectable intrahepatic cholangiocarcinoma (ICC). Not all ICC patients benefit equally well from TARE. Therefore, we sought to evaluate variables predicting progression-free survival (PFS) and overall survival (OS). Patients with non-resectable ICC underwent TARE and were treated with 90Y resin microspheres. Baseline characteristics, biochemical/clinical toxicities, and response were examined for impact on PFS and OS. A total of 103 treatments were administered to 73 patients without major complications or toxicity. Mean OS was 18.9 months (95% confidence intervals (CI); 13.9–23.9 months). Mean and median PFS were 10.1 months (95% CI; 7.9–12.2) and 6.4 months (95% CI; 5.20–7.61), respectively. Median OS and PFS were significantly prolonged in patients with baseline cholinesterase (CHE) ≥ 4.62 kU/L (OS: 14.0 vs. 5.5 months; PFS: 6.9 vs. 3.2 months; p < 0.001). Patients with a tumor burden ≤ 25% had a significantly longer OS (15.2 vs. 6.6 months; p = 0.036). Median PFS was significantly longer for patients with multiple TARE cycles (24.4 vs. 5.8 months; p = 0.04). TARE is a considerable and safe option for unresectable ICC. CA-19-9, CHE, and tumor burden have predictive value for survival in patients treated with TARE. Multiple TARE treatments might further improve survival; this has to be confirmed by further studies. MDPI 2021-10-27 /pmc/articles/PMC8582544/ /pubmed/34771563 http://dx.doi.org/10.3390/cancers13215399 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Paprottka, Karolin J.
Galiè, Franziska
Ingrisch, Michael
Geith, Tobias
Ilhan, Harun
Todica, Andrei
Michl, Marlies
Nadjiri, Jonathan
Paprottka, Philipp M.
Outcome and Safety after 103 Radioembolizations with Yttrium-90 Resin Microspheres in 73 Patients with Unresectable Intrahepatic Cholangiocarcinoma—An Evaluation of Predictors
title Outcome and Safety after 103 Radioembolizations with Yttrium-90 Resin Microspheres in 73 Patients with Unresectable Intrahepatic Cholangiocarcinoma—An Evaluation of Predictors
title_full Outcome and Safety after 103 Radioembolizations with Yttrium-90 Resin Microspheres in 73 Patients with Unresectable Intrahepatic Cholangiocarcinoma—An Evaluation of Predictors
title_fullStr Outcome and Safety after 103 Radioembolizations with Yttrium-90 Resin Microspheres in 73 Patients with Unresectable Intrahepatic Cholangiocarcinoma—An Evaluation of Predictors
title_full_unstemmed Outcome and Safety after 103 Radioembolizations with Yttrium-90 Resin Microspheres in 73 Patients with Unresectable Intrahepatic Cholangiocarcinoma—An Evaluation of Predictors
title_short Outcome and Safety after 103 Radioembolizations with Yttrium-90 Resin Microspheres in 73 Patients with Unresectable Intrahepatic Cholangiocarcinoma—An Evaluation of Predictors
title_sort outcome and safety after 103 radioembolizations with yttrium-90 resin microspheres in 73 patients with unresectable intrahepatic cholangiocarcinoma—an evaluation of predictors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582544/
https://www.ncbi.nlm.nih.gov/pubmed/34771563
http://dx.doi.org/10.3390/cancers13215399
work_keys_str_mv AT paprottkakarolinj outcomeandsafetyafter103radioembolizationswithyttrium90resinmicrospheresin73patientswithunresectableintrahepaticcholangiocarcinomaanevaluationofpredictors
AT galiefranziska outcomeandsafetyafter103radioembolizationswithyttrium90resinmicrospheresin73patientswithunresectableintrahepaticcholangiocarcinomaanevaluationofpredictors
AT ingrischmichael outcomeandsafetyafter103radioembolizationswithyttrium90resinmicrospheresin73patientswithunresectableintrahepaticcholangiocarcinomaanevaluationofpredictors
AT geithtobias outcomeandsafetyafter103radioembolizationswithyttrium90resinmicrospheresin73patientswithunresectableintrahepaticcholangiocarcinomaanevaluationofpredictors
AT ilhanharun outcomeandsafetyafter103radioembolizationswithyttrium90resinmicrospheresin73patientswithunresectableintrahepaticcholangiocarcinomaanevaluationofpredictors
AT todicaandrei outcomeandsafetyafter103radioembolizationswithyttrium90resinmicrospheresin73patientswithunresectableintrahepaticcholangiocarcinomaanevaluationofpredictors
AT michlmarlies outcomeandsafetyafter103radioembolizationswithyttrium90resinmicrospheresin73patientswithunresectableintrahepaticcholangiocarcinomaanevaluationofpredictors
AT nadjirijonathan outcomeandsafetyafter103radioembolizationswithyttrium90resinmicrospheresin73patientswithunresectableintrahepaticcholangiocarcinomaanevaluationofpredictors
AT paprottkaphilippm outcomeandsafetyafter103radioembolizationswithyttrium90resinmicrospheresin73patientswithunresectableintrahepaticcholangiocarcinomaanevaluationofpredictors